Takashi Fukuyama
Overview
Explore the profile of Takashi Fukuyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
384
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yasuoka Y, Izumi Y, Fukuyama T, Oshima T, Yamazaki T, Uematsu T, et al.
Int J Mol Sci
. 2024 Jan;
25(2).
PMID: 38279224
Many large-scale studies show that exogenous erythropoietin, erythropoiesis-stimulating agents, lack any renoprotective effects. We investigated the effects of endogenous erythropoietin on renal function in kidney ischemic reperfusion injury (IRI) using...
2.
Kaburagi Y, Kira K, Yahata K, Iso K, Sato Y, Matsuura F, et al.
Org Lett
. 2024 Jan;
26(14):2837-2842.
PMID: 38252895
E7130 is a novel drug candidate with an exceedingly complex chemical structure of the halichondrin class, discovered by a total synthesis approach through joint research between the Kishi group at...
3.
Komuro H, Shinohara S, Fukushima Y, Demachi-Okamura A, Muraoka D, Masago K, et al.
J Immunother Cancer
. 2023 Aug;
11(8).
PMID: 37544663
Background: CD8tumor infiltrating lymphocytes (TILs) are often observed in non-small cell lung cancers (NSCLC). However, the characteristics of CD8 TILs, especially T-cell populations specific for tumor antigens, remain poorly understood....
4.
Ichiki Y, Fukuyama T, Ueno M, Kanasaki Y, Goto H, Takahashi M, et al.
Transl Lung Cancer Res
. 2022 Dec;
11(11):2192-2207.
PMID: 36519023
Background: Immune checkpoint inhibitors (ICIs) have become central to lung cancer drug therapy, and establishing biomarkers that can predict effects and adverse events (AEs) is awaited. We prospectively analyzed the...
5.
Otsuka T, Fukuyama T, Futawatari N, Tahara K, Watanabe M, Ichiki Y, et al.
J Cancer
. 2022 Dec;
13(14):3526-3532.
PMID: 36484013
Kita-Kyushu lung cancer antigen-1 (KK-LC-1), encoded by , is a cancer/testis antigen (CTA) and an attractive target for immunotherapy. Our previous study demonstrated frequent expression in gastric cancers (GCs) and...
6.
Yasuoka Y, Izumi Y, Fukuyama T, Omiya H, Pham T, Inoue H, et al.
Molecules
. 2022 Feb;
27(3).
PMID: 35164384
Anemia is a major complication of chronic renal failure. To treat this anemia, prolylhydroxylase domain enzyme (PHD) inhibitors as well as erythropoiesis-stimulating agents (ESAs) have been used. Although PHD inhibitors...
7.
Ichiki Y, Fukuyama T, Ohmiya H, Ueno M, Yanagi S, Kanasaki Y, et al.
Transl Cancer Res
. 2022 Feb;
10(12):5212-5221.
PMID: 35116371
Background: Previously, we identified the highly immunogenic cancer testicular antigen named Kita-Kyushu Lung Cancer antigen-1 (KK-LC-1). In this study, we analyzed the effect of KK-LC-1 expression on the prognosis of...
8.
Ichiki Y, Ueno M, Yanagi S, Kanasaki Y, Goto H, Fukuyama T, et al.
Transl Lung Cancer Res
. 2021 Sep;
10(8):3520-3537.
PMID: 34584854
Background: Various immune cells that play a central role in antitumor immunity accumulate in primary tumors and regional lymph nodes. Such cellular accumulation and the molecular expression were analyzed to...
9.
Yasuoka Y, Izumi Y, Fukuyama T, Inoue H, Oshima T, Yamazaki T, et al.
Molecules
. 2021 Sep;
26(17).
PMID: 34500833
The kidney is a main site of erythropoietin production in the body. We developed a new method for the detection of Epo protein by deglycosylation-coupled Western blotting. Detection of deglycosylated...
10.
Yasuoka Y, Fukuyama T, Izumi Y, Yamashita T, Nakayama Y, Inoue H, et al.
Heliyon
. 2020 Nov;
6(11):e05389.
PMID: 33195841
Doping tests for the illegal use of erythropoiesis-stimulating agents (ESAs) have been developed. We developed a new Western blotting method to detect and distinguish endogenous erythropoietin (Epo, 35-38 kDa) and...